Friday, April 26, 2024
4/26/2024
PROJECT SUMMARY During chronic infections such as those caused by HIV-1, hepatitis C virus (HCV), and lymphocytic choriomeningitis virus (LCMV), as well as during tumor outgrowth, antigen-specific CD8 T cells often progressively lose function in a step-wise manner. Understanding the factors that impact CD8 T cell responses during chronic viral infections is necessary for the design of effective immunotherapeutic strategies. Recent reports demonstrate that a discrete subset of exhausted CD8 T cells exists that displays stem cell-like properties, including the ability to self-renew and further differentiate in vivo. Importantly, this subset of cells is exquisitely responsive to anti-PD-L1 immunotherapy during chronic LCMV clone 13 infection. Hence, determining the mechanisms that promote the maintenance and survival of stem-like CD8 T cells during chronic viral infection is of central importance. We present preliminary findings that show a distinct fraction of the virus-specific stem-like CD8 T cells express cell surface N-glycans with a-2,6 linked sialic acids, a posttranslational modification mediated by the glycosyltransferase ST6Gal-I. Importantly, published studies, as well as our own data, establish that this enzyme is associated with pluripotency and stemness. Together, these data lead us to hypothesize that ST6Gal-I sialylation positively regulates CD8 T cell stemness and responsiveness to immunotherapy during chronic viral infection. Our objectives of this exploratory R21 application are to: Aim 1. Determine if ST6Gal-I sialylation identifies stem-like CD8 T cells during chronic viral infection. Aim 2: Determine how modulation of ST6Gal-I sialylation impacts CD8 T cell stemness. Collectively, these studies are designed to provide new information regarding the impact of cell surface sialylation of CD8 T cell responses, including CD8 T cell stemness and exhaustion.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
